Please try another search
Jiangsu Sihuan Bioengineering Co., Ltd. engages in the pharmaceutical business in China. It offers delusen, an anti-tumor biotherapeutic drug for the treatment of kidney cancer, malignant melanoma, and cancerous chest and abdominal mass; Xinde Lusheng; Xin Lisheng; and Ring BO. It also engages in breeding and sales of flowers and seedlings; and landscaping projects. Jiangsu Sihuan Bioengineering Co., Ltd. was founded in 1992 and is headquartered in Jiangyin, China.
Name | Age | Since | Title |
---|---|---|---|
Wei Liu | 61 | 2020 | Independent Director |
Yu Guo | 35 | 2020 | GM & Chairman |
Yu Lu | - | 2023 | Non-Independent Director |
Wen Jun | 52 | 2021 | Non-Independent Director |
Lei Wang | 42 | 2020 | Shareholder Supervisor |
Yu Lu | 48 | 2023 | Non-Independent Director |
Liangwei Wu | 44 | 2023 | Independent Director |
Li Wang | - | 2023 | Independent Director |
Like Xu | 38 | 2019 | Shareholder Supervisor |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review